Latest AKRO reports update at 2024-02-29: 2023 ∙ 2022 ∙ 2021

Akero Therapeutics AKRO

$ 20.8 -1.05%

Akero Therapeutics Balance Sheet 2011-2024 | AKRO

Annual Balance Sheet Akero Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-233 M	-249 M	-149 M	-184 M	-64.8 M	-76 M	-598 K	-	-	-	-	-	-
Long Term Debt	819 K	1.08 M	1.31 M	1.52 M	-	-	-	-	-	-	-	-	-
Long Term Debt Current	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	1.52 M	23 K	125 M	5 M	-	-	-	-	-	-
Total Current Liabilities	19.1 M	19.1 M	25.1 M	13.1 M	9.37 M	-	-	-	-	-	-	-	-
Total Liabilities	45 M	30 M	26.4 M	14.6 M	9.39 M	127 M	5.22 M	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-574 M	-422 M	-310 M	-210 M	-130 M	-86.6 M	-4.56 M	-	-	-	-	-	-
Total Assets	580 M	357 M	196 M	273 M	138 M	77.2 M	658 K	-	-	-	-	-	-
Cash and Cash Equivalents	234 M	250 M	151 M	187 M	64.8 M	76 M	-	-	-	-	-	-	-
Book Value	535 M	327 M	169 M	259 M	129 M	-49.9 M	-4.56 M	-	-	-	-	-	-
Total Shareholders Equity	535 M	327 M	169 M	259 M	129 M	-49.9 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Akero Therapeutics

	2023-Q3	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	888 K	1.02 M	1.08 M	1.14 M	-	1.26 M	1.31 M	1.36 M	1.42 M	1.47 M	1.52 M	1.52 M	1.52 M	1.52 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	52.2 M	42.5 M	30 M	35.9 M	-	23.4 M	26.4 M	24.9 M	17.9 M	11.6 M	14.6 M	14.6 M	14.6 M	14.6 M	9.39 M	9.39 M	9.39 M	9.39 M	2.34 M	2.34 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-519 M	-448 M	-422 M	-399 M	-	-336 M	-310 M	-278 M	-254 M	-225 M	-210 M	-210 M	-210 M	-210 M	-130 M	-130 M	-130 M	-130 M	-86.6 M	-86.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	635 M	349 M	357 M	379 M	-	170 M	196 M	224 M	238 M	258 M	273 M	273 M	273 M	273 M	138 M	138 M	138 M	138 M	77.2 M	77.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	270 M	258 M	250 M	374 M	-	151 M	150 M	165 M	158 M	188 M	187 M	187 M	187 M	187 M	64.8 M	64.8 M	64.8 M	64.8 M	76 M	76 M	9.81 M	-	618 K	-	618 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	583 M	306 M	327 M	344 M	-	147 M	169 M	199 M	220 M	246 M	259 M	259 M	259 M	259 M	129 M	129 M	129 M	129 M	74.8 M	74.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	583 M	306 M	327 M	344 M	148 M	147 M	169 M	199 M	220 M	246 M	259 M	259 M	259 M	259 M	129 M	129 M	129 M	129 M	-49.9 M	-49.9 M	-13.7 M	-4.98 M	-4.56 M	-	-4.56 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency